Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: Effects of sex and race

摘要: Background This study investigates the association of clinical and demographic predictors with abdominal fat gain, measured using waist circumference (WC) self-reported size. Methods We analyzed data from ACTG A5257, a trial that randomized treatment-naive HIV-infected participants to 1 3 antiretroviral regimens: raltegravir (RAL) or protease inhibitors (PIs) atazanavir/ritonavir (ATV/r) darunavir/ritonavir (DRV/r), each in combination tenofovir disoproxil fumarate/emtricitabine. Associations treatment baseline/demographic characteristics 96-week WC change were assessed repeated-measures models. Ordinal logistic regression was used examine associations week 96 changes. Results The population (n = 1809) 76.0% male predominantly black non-Hispanic (41.9%) white (34.1%). Mean baseline 90.6 cm, an average increase 3.4 cm. increases higher RAL arm compared DRV/r (P .0130). Females experienced greater on vs ATV/r than males .0065). Similarly, larger difference found for nonblack individuals .0043). A separate multivariable model addition regimen, viral load lower CD4+ also associated increases. Conclusions With therapy initiation, PIs more pronounced female participants, advanced HIV disease state strong predictor Understanding factors predisposing gain could inform health management after initiation.